Hyperkalemia in a patient with advanced hepatocellular carcinoma probably due to sorafenib: case report.
Sorafenib is an oral tyrosine kinase inhibitor used in the treatment of metastatic hepatocellular carcinoma (HCC). Its common adverse reactions include diarrhea, hand-foot syndrome, rash, cardiac ischemia or infarction, hypertension, elevated serum lipase and hypophosphatemia. A 35-year-old male pat...
| Publicado en: | Turkiye Klinikleri Journal of Medical Sciences Vol. 32; no. 2; pp. 585 - 588 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | case study Journal Article |
| Publicado: |
Turkiye Klinikleri
Apr2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104546027&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104546027 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 13000292 1VOP jtl: Turkiye Klinikleri Journal of Medical Sciences issn: 13000292 maglogo: N pubinfo: dt: Apr2012 vid: 32 iid: 2 pid: 67298 pub: Turkiye Klinikleri artinfo: ui: 104546027 2011506285 10.5336/medsci.2010-21468 104546027 ppf: 585 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Hyperkalemia in a patient with advanced hepatocellular carcinoma probably due to sorafenib: case report. aug: au: Uyeturk, Ummugul Budakoglu, Burcin Helvaci, Kaan Sonmez, Ozlem Uysal Turker, Ibrahim Arslan, Ulku Yalcintas Oksuzoglu, Berna Zengin, Nurullah affil: Clinic of II. Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Training and Research Hospital, Ankara sug: subj: Benzene Derivatives Adverse Effects Benzene Derivatives Classification Carcinoma, Hepatocellular Diagnosis Carcinoma, Hepatocellular Drug Therapy Hyperkalemia Diagnosis Sorafenib Adult Male Adult: 19-44 years Male ab: Sorafenib is an oral tyrosine kinase inhibitor used in the treatment of metastatic hepatocellular carcinoma (HCC). Its common adverse reactions include diarrhea, hand-foot syndrome, rash, cardiac ischemia or infarction, hypertension, elevated serum lipase and hypophosphatemia. A 35-year-old male patient with unresectable HCC was treated with sorafenib for progressive disease after locoregional chemoembolization. In the second month of the sorafenib treatment, he was admitted to the emergency department with weakness and drowsiness. His serum potassium level was 8.3 mmol/ L (3.5-5.5 mmol/L) which was accompanied with mild elevations in liver enzymes. Sorafenib treatment was stopped and emergency hemodialysis was applied. His potassium level reduced to normal levels and was stabilized. pubtype: Academic Journal doctype: case study Journal Article ougenre: Article language: Turkish refInfo: holdings: @attributes: islocal: N |
|---|